Effects of Liraglutide on Body Surface Gastric Mapping

NCT06500130 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can change stomach activity patterns in people with gastroparesis, functional dyspepsia, or chronic nausea and vomiting, as well as in healthy individuals.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) diagnostic study

Participants 22 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2024-05 · est. completion 2024-11

Where 1 site · New Zealand

What this study is testing ClinicalTrials.gov NCT06500130 ↗

Description as written by the study sponsor.

Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of liraglutide and subsequent washout. Aim 2: Assessment of effect of liraglutide injection on gastrointestinal symptoms and gut-brain wellbeing (as measured by validated symptom App and Alimetry gut-brain wellness Scale, respectively) during an 13-day ramping dose of liraglutide and subsequent washout.

Treatments tested

Body Surface Gastric Mapping Device

All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.

Main thing measured	Change in overall postprandial BSGM Gastric Alimetry Rhythm Index (GA-RI) on treatment compared to baseline.
Sponsor	Alimetry
Conditions studied	Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06500130 ↗